China Shineway Pharmaceutical Group Future Growth

Future criteria checks 3/6

China Shineway Pharmaceutical Group is forecast to grow earnings and revenue by 14.5% and 14.5% per annum respectively. EPS is expected to grow by 13.8% per annum. Return on equity is forecast to be 16.8% in 3 years.

Key information

14.5%

Earnings growth rate

13.8%

EPS growth rate

Pharmaceuticals earnings growth	12.8%
Revenue growth rate	14.5%
Future return on equity	16.8%
Analyst coverage	Low
Last updated	07 Apr 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

SZSC:2877 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	7,002	1,505	1,368	1,460	3
12/31/2025	6,056	1,308	900	1,269	3
12/31/2024	5,239	1,129	533	829	3
12/31/2023	4,517	970	788	933	N/A
9/30/2023	4,525	926	795	957	N/A
6/30/2023	4,534	883	801	982	N/A
3/31/2023	4,242	803	891	1,046	N/A
12/31/2022	3,951	723	980	1,110	N/A
9/30/2022	3,718	651	814	941	N/A
6/30/2022	3,485	579	648	772	N/A
3/31/2022	3,354	568	629	738	N/A
12/31/2021	3,224	557	610	703	N/A
9/30/2021	3,122	453	609	690	N/A
6/30/2021	3,020	350	608	677	N/A
3/31/2021	2,838	322	590	658	N/A
12/31/2020	2,656	295	573	639	N/A
9/30/2020	2,592	382	485	561	N/A
6/30/2020	2,528	469	397	483	N/A
3/31/2020	2,617	486	337	426	N/A
12/31/2019	2,706	503	277	368	N/A
9/30/2019	2,670	520	289	382	N/A
6/30/2019	2,633	537	301	396	N/A
3/31/2019	2,602	521	347	465	N/A
12/31/2018	2,570	506	393	533	N/A
9/30/2018	2,492	516	390	521	N/A
6/30/2018	2,413	526	388	509	N/A
3/31/2018	2,166	489	393	500	N/A
12/31/2017	1,920	452	399	491	N/A
9/30/2017	1,897	474	N/A	588	N/A
6/30/2017	1,873	496	N/A	685	N/A
3/31/2017	1,933	542	N/A	709	N/A
12/31/2016	1,993	589	N/A	734	N/A
9/30/2016	1,935	569	N/A	709	N/A
6/30/2016	1,877	549	N/A	685	N/A
3/31/2016	1,966	603	N/A	715	N/A
12/31/2015	2,055	658	N/A	745	N/A
9/30/2015	2,147	672	N/A	723	N/A
6/30/2015	2,239	685	N/A	701	N/A
3/31/2015	2,234	695	N/A	737	N/A
12/31/2014	2,229	705	N/A	773	N/A
9/30/2014	2,228	704	N/A	740	N/A
6/30/2014	2,227	703	N/A	706	N/A
3/31/2014	2,207	693	N/A	613	N/A
12/31/2013	2,187	684	N/A	520	N/A
9/30/2013	2,188	681	N/A	589	N/A
6/30/2013	2,189	678	N/A	657	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2877's forecast earnings growth (14.5% per year) is above the savings rate (2.2%).

Earnings vs Market: 2877's earnings (14.5% per year) are forecast to grow faster than the Hong Kong market (12.1% per year).

High Growth Earnings: 2877's earnings are forecast to grow, but not significantly.

Revenue vs Market: 2877's revenue (14.5% per year) is forecast to grow faster than the Hong Kong market (8.1% per year).

High Growth Revenue: 2877's revenue (14.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 2877's Return on Equity is forecast to be low in 3 years time (16.8%).

China Shineway Pharmaceutical Group Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Recent updates

Full year 2023 earnings released: EPS: CN¥1.28 (vs CN¥0.96 in FY 2022)

Upcoming dividend of HK$0.46 per share

Final dividend of HK$0.46 announced

China Shineway Pharmaceutical Group Limited Declares First Interim Dividend in Respect of the Year Ending December 31, 2024, Payable on May 17, 2024

China Shineway Pharmaceutical Group Limited, Annual General Meeting, May 31, 2024

China Shineway Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Less than half of directors are independent

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies